This application is a competing renewal of an R01 grant subsequently modified to R37 status following a Merit Award from NIDA. The initial application proposed """"""""to correlate the molecular properties of cannabimimetic agents with their biochemical/pharmacological properties"""""""" in order to identify the pharmacophoric profiles of key compound classes that directly modulate the functions of the CB1 and CB2 cannabinoid receptors (CBRs). This information was used to design, synthesize and develop later generation CBR (ant) agonists with distinct pharmacological profiles either as molecular probes or leads for medications development. All of the above goals were completed. During this project period, we were motivated to extend our goals by new findings on the effects of enzymatic endocannabinoid deactivation by specific esterases. We now propose to study the three key brain esterases involved in endocannabinoid deactivation, namely, monoacyl glycerol lipase (MGL), fatty acid amide hydrolase (FAAH) and ?/?-hydrolase domain-containing 6 (ABHD6) for their structural and functional properties. Inhibition of these enzymes enhances endocannabinoid levels, indirectly activates cannabinoid receptors and modulates cannabinergic signaling. All three enzymes have been implicated in mechanisms associated with addiction and pain and are potentially useful targets for therapeutic intervention. The proposed work will be carried out using ligands that interact covalently or non-covalently with each of the enzymes and will include mass spectrometry and nuclear magnetic resonance experiments to obtain detailed structural and functional information for each of the enzymes. The results will be used to design and synthesize selective reversible and irreversible inhibitors with optimized pharmacological profiles for each of the enzymes. Additionally, we propose to develop selective ligands possessing dual action with equal ability to inactivate two enzymes. Successful inhibitors will serve as useful pharmacological probes to study the endocannabinoid system as well as leads for the development of medications for addiction and pain management.

Public Health Relevance

The application proposes to study the structural and functional properties of three key endocannabinoid deactivating brain enzymes using biochemical and biophysical methods. The information will be used to design and develop novel enzyme inhibitors with single and dual action as probes for pharmacological research or as leads for the development of medications for addiction and pain.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MDCN-C (58))
Program Officer
Hillery, Paul
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northeastern University
Schools of Pharmacy
United States
Zip Code
Mallipeddi, Srikrishnan; Zvonok, Nikolai; Makriyannis, Alexandros (2018) Expression, Purification and Characterization of the Human Cannabinoid 1 Receptor. Sci Rep 8:2935
Yu, Tianqi; Ganapathy, Suthakar; Shen, Ling et al. (2018) A lethal synergy induced by phellinus linteus and camptothecin11 in colon cancer cells. Oncotarget 9:6308-6319
Schindler, Charles W; Scherma, Maria; Redhi, Godfrey H et al. (2016) Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys. Psychopharmacology (Berl) 233:1867-77
Pava, Matthew J; Makriyannis, Alexandros; Lovinger, David M (2016) Endocannabinoid Signaling Regulates Sleep Stability. PLoS One 11:e0152473
Parker, Linda A; Limebeer, Cheryl L; Rock, Erin M et al. (2016) A comparison of novel, selective fatty acid amide hydrolase (FAAH), monoacyglycerol lipase (MAGL) or dual FAAH/MAGL inhibitors to suppress acute and anticipatory nausea in rat models. Psychopharmacology (Berl) 233:2265-75
Schindler, Charles W; Redhi, Godfrey H; Vemuri, Kiran et al. (2016) Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys. Neuropsychopharmacology 41:2283-93
Guo, Jason J; Yang, De-Ping; Tian, Xiaoyu et al. (2016) 17?-estradiol (E2) in membranes: Orientation and dynamic properties. Biochim Biophys Acta 1858:344-53
Kulkarni, Shashank; Nikas, Spyros P; Sharma, Rishi et al. (2016) Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. J Med Chem 59:6903-19
Tyukhtenko, Sergiy; Karageorgos, Ioannis; Rajarshi, Girija et al. (2016) Specific Inter-residue Interactions as Determinants of Human Monoacylglycerol Lipase Catalytic Competency: A ROLE FOR GLOBAL CONFORMATIONAL CHANGES. J Biol Chem 291:2556-65
Panlilio, Leigh V; Thorndike, Eric B; Nikas, Spyros P et al. (2016) Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats. Psychopharmacology (Berl) 233:1879-88

Showing the most recent 10 out of 192 publications